Christopher Talbot

Professor of Radiotherapy Genetics

University of Leicester
Country flagUnited Kingdom
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (2)

Purpose: Genome-wide association studies are the gold standard for identifying SNP associated with rectal toxicity after prostate cancer radiotherapy. However, they often neglect the radiotherapy dose distribution, which is a key contributor to toxicity risk. Here, we combined rectal dose surface maps with genetic data to identify rectal regions in which variants influence dose–toxicity relationships. Experimental Design: Data were analyzed from 1,293 patients with prostate cancer from the REQUITE study. Deep learning rectum contouring ensured consistent segmentation, and rectum lengths were standardized to generate two-dimensional dose surface maps. Patients were categorized based on the presence of risk alleles for three candidate SNP (rs1801516, rs17055178, and rs17630638). Propensity score matching accounted for age, rectal volume, prostate volume, and hormone therapy. Voxel-wise Cox proportional hazards models with permutation testing assessed dose–toxicity associations. Results: Voxel-wise Cox proportional hazards models revealed significant ( P Conclusions: This study identified genotype-driven toxicity patterns using spatial dose mapping. By revealing consistent high-risk rectal regions, this approach strengthens the link between genomics and radiotherapy planning. Importantly, modern radiotherapy planning makes it feasible to reduce dose in genetically sensitive patients and move toward more personalized treatment.

Year:

2025

Background: Late bladder toxicity is a concern for patients receiving prostate cancer radiotherapy and negatively affects survivors. Few risk factors are known beyond the radiation dose and volume of bladder exposed. A polygenic risk score (PRS) could identify susceptible patients. Methods: A PRS was built using genome-wide association results from the Radiogenomics Consortium ( N = 3,988) and then tested in the prospective REQUITE and URWCI studies ( N = 2,034). The primary outcome was time to patient–reported gross [grade ≥2, (≥G2)] hematuria, analyzed using Cox proportional hazards regression. Secondary outcomes were ≥G2 urinary retention and frequency. The PRS was externally validated for clinically diagnosed irradiation cystitis in the UK Biobank ( N = 8,430). A gene-burden test evaluated rare coding variants. Results: A 115-variant PRS was associated with a significantly increased risk of ≥G2 hematuria [hazard ratio (HR) per SD = 1.22; P = 0.009] as well as urinary retention (HR per SD = 1.18; P = 0.016) and frequency (HR per SD = 1.14; P = 0.036). When binarized, men in the upper decile (PRS high ) had a >2-fold increased risk of hematuria after adjusting for clinical risk factors [HR = 2.12; P = 0.002; Harrel’s concordance index = 0.71 (95% confidence interval, 0.65–0.76)]. A similar effect size was seen in the UK Biobank for clinically diagnosed irradiation cystitis [odds ratio (OR) = 2.15; P = 0.026]. The burden test identified BOD1L1 as a putative novel radiosensitivity gene. Conclusions: This PRS identifies susceptible patients and could guide the selection of those needing reoptimized treatment plans that spare the bladder beyond currently recommended constraints. Impact: PRS-guided treatment planning in radiation oncology could lower the incidence of clinically relevant bladder toxicity and reduce the impact of this outcome on prostate cancer survivors.

Year:

2025

Collaborators (16)

William A. Hall

-

UNITED STATES
View details

Barbara Avuzzi

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Jane Shortall

The University of Manchester

UNITED KINGDOM
View details

Alison Margaret Dunning

University of Cambridge

UNITED KINGDOM
View details

Brian Marples

Dr. Sidney H. and Barbara L. Sobel Professor in Radiation Oncology

University of Rochester Medical Center

UNITED STATES
View details

Harry Ostrer

Professor

Yeshiva University Albert Einstein College of Medicine

UNITED STATES
View details

Alan Mcwilliam

University of Manchester

UNITED KINGDOM
View details

Marcel van Herk

The University of Manchester

UNITED KINGDOM
View details

Paul Auer

Professor

Medical College of Wisconsin

UNITED STATES
View details

Michelle C. Janelsins

Division Chief and Professor

University of Rochester Medical Center

UNITED STATES
View details

Tiziana Rancati

Researcher

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Ananya Choudhury

The University of Manchester

UNITED KINGDOM
View details

Edward Messing

Professor

University of Rochester Medical Center

UNITED STATES
View details

Catharine West

The University of Manchester

UNITED KINGDOM
View details

Andrew Morris

The University of Manchester

UNITED KINGDOM
View details

Sarah Kerns

Associate Professor

Medical College of Wisconsin

UNITED STATES
View details